JAK Inhibitors in Inflammatory Skin Diseases: A 15,427-Patient Systematic Review and Meta-analysis of Clinical Trial and Real-World Outcomes.
Nada Faheem Zayed, Khaled Seetan, Almu'atasim Khamees et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness and safety of JAK inhibitors in 15,427 patients with inflammatory skin diseases, including atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hidradenitis suppurativa. The study found EASI-75 response rates for atopic dermatitis ranged from 38 to 73%, indicating significant efficacy compared to placebo.
Key findings
- EASI-75 response rates for atopic dermatitis ranged from 38 to 73%.
- PASI-75 rates for psoriasis ranged from 33 to 67%.
- SALT-50 rates for alopecia areata ranged from 30 to 62%.
- Upper respiratory infections occurred in 5-14% of patients treated with JAK inhibitors.
Why it matters
Understanding the efficacy and safety profiles of JAK inhibitors is crucial for clinicians managing inflammatory skin diseases, as these medications are increasingly utilized in practice. The findings can guide treatment decisions and patient counseling regarding potential risks and benefits.
What to keep in mind
The study acknowledges limitations including the short duration of controlled trials and under-representation of diverse populations.